TP53 and colorectal carcinoma: p53 signalling and DNA MMR have been identified as potential molecular targets for NSAIDs (Ruschoff et al, 1998; Shao et al, 2000; Goel et al, 2003), suggesting that the anti-tumour effect may, in part, involve countering the effects of genetic instability in CRC.